
Reset all filters
01 1Harnal
02 6Harnal/Omnic
03 1Omnic
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 351
2019 Revenue in Millions : 411
Growth (%) : -15
Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 226
2020 Revenue in Millions : 349
Growth (%) : -30
Main Therapeutic Indication : Nephrology
Currency : USD
2022 Revenue in Millions : 69
2021 Revenue in Millions : 72
Growth (%) : -4
Main Therapeutic Indication : Nephrology
Currency : USD
2022 Revenue in Millions : 215
2021 Revenue in Millions : 227
Growth (%) : -5
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 427
2017 Revenue in Millions : 239
Growth (%) : 79%
Main Therapeutic Indication : Renal Disorders
Currency : USD
2016 Revenue in Millions : 426
2015 Revenue in Millions : 494
Growth (%) : -14
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 417
2018 Revenue in Millions : 441
Growth (%) : -5
Main Therapeutic Indication : Renal Disorders
Currency : USD
2017 Revenue in Millions : 254
2016 Revenue in Millions : 454
Growth (%) : -44